EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma-Reference-Cited by-同舟云学术

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Published:2023-11 Issue:11 Volume:34 Page:1047-1054
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rosenberg J.E.,Powles T.,Sonpavde G.P.,Loriot Y.,Duran I.,Lee J.-L.,Matsubara N.,Vulsteke C.,Castellano D.,Mamtani R.,Wu C.,Matsangou M.,Campbell M.,Petrylak D.P.

Funder

Astellas Pharma US

Seagen

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference14 articles.

1. National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Bethesda, MD, 2023. Available at https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer. Accessed October 10, 2023.

2. EAU guidelines on muscle-invasive and metastatic bladder cancer;Witjes,2022

3. Treatment of muscle-invasive and advanced bladder cancer in 2020;Patel;CA Cancer J Clin,2020

4. Cancer.Net Editorial Board. Bladder Cancer Guide. Available at https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed October 10, 2023. 2021.

5. Efficacy and adverse events of PD-1 inhibitors in patients with advanced urothelial carcinoma from a real-world experience;Sun;Front Pharmacol,2022

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives;International Journal of Molecular Sciences;2024-09-07

2. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

3. Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis;The French Journal of Urology;2024-09

4. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

5. Emerging molecular therapies in the treatment of bladder cancer;Exploration of Targeted Anti-tumor Therapy;2024-08-29